Voice of Zhejiang, January 11 (Reporter Zhang Yuan, Correspondent Qian Lingyun) Tonglu County, Hangzhou, with its beautiful mountains and clear waters, has been committed to building a big health industry over the years. Today, the annual report meeting of China's pharmaceutical and biotechnology industry in Fuchun Mountain and the 2019 top ten progress conference of China's pharmaceutical and biotechnology were held here again. It showed the industry the new progress and achievements of my country's pharmaceutical biotechnology industry in 2019.

Nearly 200 academicians of the Chinese Academy of Sciences and the Chinese Academy of Sciences, well-known biomedical experts, and business leaders were present at the conference to discuss the development of the biomedical industry.

At the meeting, ten major advances in China's pharmaceutical biotechnology in 2019 were announced. Shanghai WuXi AppTec New Drug Development Co., Ltd., Hangzhou Wutongshu Pharmaceutical Co., Ltd. and Wei Yuquan, academician of the Chinese Academy of Sciences, director of the State Key Laboratory of Biotherapy of Sichuan University, chairman of the China Association of Pharmaceutical Biotechnology, and Tonglu County People's Government signed a small molecule targeting agreement. Drug R&D transformation project strategic cooperation agreement, the first batch of 5 first-class new drug R&D was launched, and it is expected to enter the clinical stage this year, bringing good news to the majority of cancer patients.

Academician Wei Yuquan said, "The new drugs signed this time are all small-molecule targeted drugs, which are mainly used for the treatment of lung cancer, liver cancer, colon cancer and some immune diseases. After the first batch of five new drugs entered the clinic this year, it is expected that there will be more drugs next year. There will be six new drugs that will enter the clinic."

Fang Suping, chairman of Hangzhou Wutongshu Pharmaceutical Co., Ltd., a company involved in drug research and development, said: "The research and development of new drugs is a long process, which requires not only a large amount of capital investment, but also the companies and researchers involved in the research and development. Lonely and able to withstand failure. At present, most domestic anti-cancer drugs still rely on imports. It is hoped that through their efforts, more innovative drug research and development in China will be launched in the near future. good treatment."

As the permanent location of the ten major progress conferences of China's pharmaceutical and biotechnology, Tonglu actively responds to the "Healthy China Strategy", seizes the opportunities of the times in the life and health industry, and actively practices the lucid waters and lush mountains by relying on its own advantages as the origin of traditional Chinese medicine in China. It is the concept of Jinshan Yinshan, taking big health as one of the three leading industries in the county, and focusing on strengthening and expanding the big health industry.

In May 2019, the first national-level life and health industry pilot zone in the Yangtze River Delta, "China Hangzhou Tonglu (International) Life and Health Industry Pilot Zone" was officially settled in Tonglu, which added a lot of splendor to Tonglu's development of the big health industry. a sum of. In October 2019, the Fuchunshan Health City Management Committee and China Youth Urban Investment Holding Group Co., Ltd. signed the "Investment Agreement" for the China Youth Five-Star Health City project with a total investment of about 3 billion yuan. In November 2019, the Fuchun Mountain Health City with a total construction area of about 85,000 square meters welcomed the successful opening of Tonglu Fengqi Life Port, creating an "incubation-acceleration" base for the entrepreneurial and innovative development of biotechnology companies.

Next, Tonglu will continue to expand Tonglu's popularity and influence in the field of biotechnology across the country, and help create a national-level life and health industry pilot zone.

Attached:

The results of the selection of the top ten progress in China's pharmaceutical biotechnology in 2019 are (in no particular order)

1. Important progress has been made in vaccine management and product development

In order to promote the healthy development and industrial innovation of the vaccine industry and ensure the safety, effectiveness and accessibility of vaccines, in 2019, my country promulgated the world's first comprehensive vaccine management law - the "Vaccine Management Law". Important progress has been made in vaccine research and development after the promulgation of the law. Among them, the 13-valent pneumococcal polysaccharide conjugate vaccine of Yuxi Watson Biotechnology Co., Ltd. was approved for marketing, which is of positive significance for the prevention of pneumonia in infants and children; Xiamen Wantai Canghai Biotechnology Co., Ltd. The bivalent human papillomavirus vaccine was approved for marketing, which is the first domestically approved human papillomavirus vaccine; the quadrivalent recombinant norovirus vaccine of the Pasteur Institute of Shanghai, Chinese Academy of Sciences entered clinical trials.

2. Domestic biosimilars are approved for marketing

In 2019, a total of 3 domestic biosimilars were approved for marketing. Among them, rituximab injection developed by Shanghai Fuhong Henlius Biopharmaceutical Co., Ltd. was approved by the State Drug Administration for marketing, mainly for non-Hodgkin's lymphoma Adalimumab injection developed by Bio-Tech Biopharmaceutical Co., Ltd. was approved by the State Drug Administration for the treatment of autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriasis; The bevacizumab injection developed by Qilu Pharmaceutical Co., Ltd. has been approved by the State Drug Administration for marketing, and is mainly used for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer.

3. Oral insulin completes phase II clinical trial

The oral insulin developed by Hefei Tianmai Biotechnology Development Co., Ltd. uses technologies such as controlled-release capsule selection and particle encapsulation, which overcomes the key bottleneck of oral protein administration. The oral insulin completed a Phase IIb clinical trial in the United States in 2019, and is conducting a Phase I clinical trial in China. It has a good hypoglycemic effect and provides a more convenient treatment for diabetic patients to control their blood sugar.

4. New breakthroughs in gene and cell therapy

The research team of Peking University-Tsinghua University Life Science Joint Center, Beijing You'an Hospital Affiliated to Capital Medical University, and the Fifth Medical Center of PLA General Hospital used gene-edited stem cells to treat AIDS and leukemia, and preliminarily confirmed its feasibility and safety, the study published In the New England Journal of Medicine. The non-viral vector CD19 CAR-T cell injection developed by Shanghai Cell Therapy Group has been approved by the State Drug Administration to conduct clinical trials for CD19-positive adult relapsed or refractory diffuse large B-cell lymphoma. It is currently the first in China. CAR-T cell therapy products made from non-viral vectors entering clinical trials. The human-derived adipose-derived mesenchymal progenitor cell injection developed by Sibiman Biotechnology Group for the treatment of knee osteoarthritis has obtained an implied license for clinical trials, becoming the first domestic stem cell clinical research record and entry after the promulgation of the new relevant guidelines. Stem cell products in clinical trials.

5. The first national standard in the field of biobanking in my country was released

The first national standard GB/T 37864 of my country's biological sample bank was officially released in 2019. The standard is completed on the basis of ten years of industry standard practice organized by the Biobank Branch of the China Medical Biotechnology Association. Standardized, high-quality biobanks are major national strategic resources, major basic projects involving national security, and are of great value to innovative basic clinical and translational research. The release of this standard marks that the construction of biological sample banks in my country has entered the era of comprehensive standardization and is at the forefront of the world.

6. Anti-infective drug Climycin, developed by synthetic biology technology, obtained new drug certificate

The innovative drug Crimycin, jointly developed by the Institute of Pharmaceutical Biotechnology of the Chinese Academy of Medical Sciences and Shenyang Tonglian Group Co., Ltd., has obtained a new drug certificate issued by the State Drug Administration. The drug uses synthetic biology technology to transform strains, the production process is simple, and the process is more environmentally friendly. It has obtained 41 patents in 16 countries.

7. Industrial application of new biomaterials

The "Acellular Corneal Implant" developed by Qingdao Zhonghao Bioengineering Co., Ltd. was approved by the State Drug Administration for marketing. This product is used for patients with fungal corneal ulcers that do not involve full thickness and who have been ineffective after systemic medication for more than two weeks or who are deemed to be indications for surgery by clinicians. The regenerative silicon material developed by Beijing Xingfuyisheng High-tech Co., Ltd. has achieved industrial application. This material is a regenerative medical biomaterial that can quickly bond and repair bones and soft tissues. It can be widely used in the prevention and treatment of various diseases.

8. HIV urine self-test reagent approved for marketing

The "Human Immunodeficiency Virus Type 1 Urine Antibody Detection Kit (Colloidal Gold Method)" jointly developed by the National Infectious Disease Diagnostic Reagent and Vaccine Engineering Technology Research Center of Xiamen University and Beijing Wantai Bio-Pharmaceutical Co., Ltd. has won the National Class III Medical Treatment The device registration certificate has been launched, and the product can detect HIV infection through urine, which can be operated and interpreted by non-professionals, filling the relevant technical gap.

9. The artificial intelligence-aided diagnosis system for endoscopy of upper gastrointestinal malignant tumors was successfully developed

Multidisciplinary experts from Sun Yat-Sen University Affiliated Cancer Hospital jointly tackled key problems and successfully developed an endoscopic artificial intelligence-assisted diagnosis system for upper gastrointestinal malignant tumors with independent intellectual property rights. The system has been verified by multi-center research in many hospitals in China, and the diagnostic accuracy rate of upper gastrointestinal malignant tumors is over 90%. The results were published in The Lancet? Oncology.

10. Chinese scientists discover high-risk subtype of EBV in nasopharyngeal carcinoma

Sun Yat-Sen University Cancer Center has found EBV subtypes that are highly correlated with the risk of nasopharyngeal cancer through full sequencing analysis of EBV from high-incidence and low-incidence areas of nasopharyngeal cancer. This high-risk subtype is of great significance for the development of preventive vaccines for nasopharyngeal carcinoma and early screening of high-risk groups. The study was published in Nature Genetics.